DAR No 6. Tapentadol (Palexia®) for chronic intense pain

Content tools

Share it

Prolonged release opioid of unknown therapeutic value

Tapentadol has proved more effective than placebo in arthrosis, lumbalgia and pain related to diabetic neuropathy.
However, the results should be interpreted with caution as there are important limitations.
No direct comparisons have been made with other opioids. There is only one analysis in which tapentadol did not show any differences when compared to oxycodone.
No studies are available on its use for pain in cancer patients.
This drug has the same adverse effect profile as other opioid analgesics. The most frequent are nausea, constipation, dizzyness, somnolence and cefalea.
There are no rapid release presentations.

Enviar comentario

You can send us a comment or suggestion and we will respond to most frequently asked questions

Competing interests (complete this field only if you have competing interests)

First name, middle initial and last name *

Email *

Current position or occupation *

Place of work *

Suggestions/Comments *